Table 3

Predictive factors of overall survival in patients from the radiation group (univariate and multivariate analysis)

VariablesUnadjusted HR (95% CI)p ValueAdjusted HR (95% CI)p Value
Preprocedure
 Age (years)1.02 (0.98 to 1.06)0.28 
 Female sex0.92 (0.34 to 2.47)0.87 
 Body mass index (kg/m²)0.95 (0.83 to 1.09)0.44 
 Previous cardiac surgery1.43 (0.50 to 4.12)0.51 
 Coronary artery disease >50%0.58 (0.22 to 1.57)0.29 
 Previous cerebrovascular accident3.10 (0.38 to 24.87)0.30 
 Extracardiac arteriopathy6.71 (1.47 to 30.51)0.0143.21 (3.79 to 492.97)0.002
 Atrial fibrillation1.89 (0.71 to 5.01)0.20 
 Pacemaker0.71 (0.16 to 3.17)0.66 
 Respiratory insufficiency2.79 (1.02 to 7.63)0.046 
 Hodgkin's disease0.44 (0.15 to 1.29)0.13 
 Time between last irradiation and TAVI (years)0.97 (0.94 to 1.00)0.08 
 Porcelain aorta1.47 (0.68 to 3.82)0.21 
 Active smoking0.05 (0.00 to 4589)0.60 
 Hypertension1.08 (0.41 to 2.81)0.88 
 Dyslipidemia0.52 (0.18 to 1.53)0.23 
 NYHA III–IV classes2.0 (0.45 to 8.85)0.36 
 CCS class 41.30 (0.17 to 9.99)0.80 
 Syncope0.36 (0.05 to 2.75)0.32 
Congestive on admission0.59 (0.22 to 1.60)0.30 
 No β-blockers before TAVI2.87 (1.06 to 7.80)0.047.80 (1.84 to 33.0)0.005
 Systolic BP (mm Hg)0.99 (0.97 to 1.02)0.62 
 Diastolic BP (mm Hg)1.01 (0.97 to 1.04)0.77 
 Heart rate (bpm)1.07 (1.02 to 1.12)0.006 
 Charlson comorbidity index1.32 (1.05 to 1.66)0.016 
 France 2 score1.30 (0.95 to 1.79)0.11 
 Creatinine clearance (mL/min)0.99 (0.97 to 1.01)0.29 
 C reactive protein level (mg/L)1.02 (1.00 to 1.04)0.08 
 Haemoglobin (g/dL)1.02 (0.76 to 1.38)0.88 
Transthoracic echocardiography
 Aortic valve area (cm²/m²)0.37 (0.03 to 4.74)0.44 
 Aortic velocity peak (cm/s)1.00 (0.99 to 1.01)0.73 
 Mean aortic gradient (mm Hg)1.01 (0.98 to 1.04)0.54 
 LVEF (%)1.01 (0.97 to 1.06)0.64 
 Systolic PAP (mm Hg)1.01 (0.98 to 1.04)0.63 
 Mitral regurgitation ≥2/41.30 (0.37 to 4.62)0.68 
 Bicuspid aortic valve1.69 (0.38 to 7.57)0.49 
Procedure
 Transfemoral access0.78 (0.22 to 2.75)0.69 
 Type of prosthetic valve (Edwards vs CoreValve)0.74 (0.26 to 2.14)0.58 
Day 7 transthoracic echocardiography
 Paraprosthetic AR ≥2/42.87 (0.61 to 13.63)0.18 
 Mitral regurgitation ≥2/413.43 (1.84 to 97.76)0.010 
 LVEF (%)1.02 (0.98 to 1.08)0.35 
 Aortic velocity peak (cm/s)0.99 (0.98 to 1.00)0.18 
 Mean aortic gradient (mm Hg)0.89 (0.79 to 1.01)0.11 
 Systolic PAP (mm Hg)1.02 (1.00 to 1.05)0.043 
Postprocedure
 Creatinine level peak (µmol/L)1.02 (1.01 to 1.03)0.0061.02 (1.01 to 1.04)0.009
 Severe bleeding1.45 (0.46 to 4.55)0.53 
 Vascular complications (access-related)2.60 (0.72 to 9.43)0.146 
 Infectious complications3.97 (1.01 to 15.57)0.0488.93 (1.74 to 45.77)0.009
 Haemodynamic complications4.59 (1.59 to 13.25)0.005 
Conduction disorders1.39 (0.43 to 4.46)0.58 
 Pacemaker neoimplantation1.18 (0.27 to 5.23)0.83 
 Supraventricular arrhythmia4.37 (0.87 to 21.91)0.07
  • Data are presented as median 25–75th percentiles or n (%).

  • AR, aortic regurgitation; BP, blood pressure; CCS, Canadian Cardiovascular Society; LVEF, left ventricle ejection fraction; NYHA, New York Heart Association; PAP, pulmonary arterial pressure; TAVI, transcatheter aortic valve implantation.